XtalPi, a US-based pharmaceutical technology company, announced on Thursday that it has entered into a strategic collaboration with Hong Kong-based CK Life Sciences, a member of the CK Hutchison Group.

The collaboration is intended to allow both companies to use their respective expertise to jointly develop a novel AI tumour vaccine R&D platform to improve the discovery and design capabilities of tumour vaccines and expedite the development of more vaccine types. The aim of the partnership is to realise precision treatment for patients globally.

The partnership will include XtalPi's industry expertise in AI computation and robotic automation to build an AI tumour vaccine R&D platform that implements advanced AI algorithms and high-precision molecular modelling to predict and design various tumour vaccines that can activate specific immune responses to kill tumours.

Dr Shuhao Wen, XtalPi co-founder and chairman, said, 'As a company headquartered in the Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone, XtalPi is committed to realising the synergies between Shenzhen and Hong Kong by creating a new paradigm for innovation in the Greater Bay Area. Empowered by the latest technological advancements in automation, artificial intelligence is accelerating more innovative and diverse areas in drug research and development. Together with CK Life Sciences, we are committed to overcome conventional limitations and discover diverse applications for cutting-edge technologies. We believe the AI cancer vaccine platform jointly developed by CK Life Sciences and XtalPi will inspire the global scientific community to progress vaccine research and development and fast-track key development milestones for cancer vaccines. We are confident that this collaboration will significantly facilitate the scientific research exchange in the Greater Bay Area.'